Table 2.
Prevalence of metabolic syndrome and its contributing factors at baseline and post-intervention, n = 221
| Baseline, mean (SD*) | Post-intervention, mean (SD*) | Mean (SD*) reduction or n (%) Change | p-valuea (UBF) | |
|---|---|---|---|---|
| Metabolic syndrome, n (%) | 93 (42.08) | 69 (31.22) | −24 (−10.86) | 0.0057 (12.49) |
| Metabolic syndrome score | 2.35 (0.98) | 2.14 (0.96) | −0.21 (0.75) | 0.0012 (45.58) |
| Waist circumference (inches) | 41.45 (6.08) | 39.81 (5.85) | −1.64 (2.33) | <0.0001 (>50) |
| SBP (mmHg) | 128.20 (19.09) | 124.34 (15.10) | −3.86 (13.11) | 0.0016 (35.72) |
| DBP (mmHg) | 82.22 (10.69) | 80.12 (9.18) | −2.10 (7.97) | 0.0037 (17.76) |
| Fasting blood glucose (mg/dL) | 89.88 (11.54) | 90.17 (9.47) | 0.29 (7.09) | 0.6774 (1.39) |
| HDL cholesterol (mg/dL) | 55.87 (13.94) | 53.44 (11.93) | −2.43 (6.46) | 0.0012 (45.58) |
| Triglyceride (mg/dL) | 113.63 (50.65) | 97.34 (29.60) | −16.29 (42.27) | 0.0007 (>50) |
| 10-year CVD risk score | 4.21 (6.86) | 3.73 (5.80) | −0.47 (2.52) | 0.0195 (4.79) |
*
Estimation of SD accounted the effect of multiple imputation in accordance with ITT analysis.
a
p-value adjusted for cluster effects and repeated measures and representing the statistical significance of mean reduction or percentage change.
UFB: upper bound of Bays factor. SBP: Systolic Blood Pressure. DBP: Diastolic Blood Pressure. HDL: High density lipoprotein. CVD: Cardiovascular disease.